Aspen Technology (AZPN) Stock Value Rose While Provident Investment Management Has Cut Its Stake by $987,474; Cytokinetics (CYTK) Stake Boosted by Essex Investment Management Co Llc

January 14, 2018 - By olga

Essex Investment Management Co Llc increased its stake in Cytokinetics Inc (CYTK) by 69.27% based on its latest 2017Q3 regulatory filing with the SEC. Essex Investment Management Co Llc bought 32,229 shares as the company’s stock rose 26.22% with the market. The hedge fund held 78,758 shares of the health care company at the end of 2017Q3, valued at $1.14 million, up from 46,529 at the end of the previous reported quarter. Essex Investment Management Co Llc who had been investing in Cytokinetics Inc for a number of months, seems to be bullish on the $476.88 million market cap company. The stock increased 0.57% or $0.05 during the last trading session, reaching $8.85. About 181,252 shares traded. Cytokinetics, Incorporated (NASDAQ:CYTK) has risen 88.33% since January 14, 2017 and is uptrending. It has outperformed by 71.63% the S&P500.

Provident Investment Management Inc decreased its stake in Aspen Technology Inc (AZPN) by 3.74% based on its latest 2017Q3 regulatory filing with the SEC. Provident Investment Management Inc sold 15,927 shares as the company’s stock rose 2.19% with the market. The institutional investor held 409,780 shares of the technology company at the end of 2017Q3, valued at $25.74M, down from 425,707 at the end of the previous reported quarter. Provident Investment Management Inc who had been investing in Aspen Technology Inc for a number of months, seems to be less bullish one the $5.45 billion market cap company. The stock increased 1.55% or $1.15 during the last trading session, reaching $75.12. About 330,256 shares traded. Aspen Technology, Inc. (NASDAQ:AZPN) has risen 59.88% since January 14, 2017 and is uptrending. It has outperformed by 43.18% the S&P500.

Analysts await Aspen Technology, Inc. (NASDAQ:AZPN) to report earnings on January, 25. They expect $0.45 EPS, down 6.25% or $0.03 from last year’s $0.48 per share. AZPN’s profit will be $32.64M for 41.73 P/E if the $0.45 EPS becomes a reality. After $0.47 actual EPS reported by Aspen Technology, Inc. for the previous quarter, Wall Street now forecasts -4.26% negative EPS growth.

Provident Investment Management Inc, which manages about $417.42 million and $590.08 million US Long portfolio, upped its stake in Abbott Labs (NYSE:ABT) by 48,232 shares to 492,917 shares, valued at $26.30 million in 2017Q3, according to the filing. It also increased its holding in Dollar Gen Corp New (NYSE:DG) by 4,762 shares in the quarter, for a total of 268,575 shares, and has risen its stake in S&P Global Inc.

Investors sentiment increased to 0.83 in 2017 Q3. Its up 0.05, from 0.78 in 2017Q2. It is positive, as 23 investors sold AZPN shares while 97 reduced holdings. 35 funds opened positions while 65 raised stakes. 72.32 million shares or 3.23% less from 74.74 million shares in 2017Q2 were reported. Moreover, Da Davidson & has 0% invested in Aspen Technology, Inc. (NASDAQ:AZPN) for 3,646 shares. Pennsylvania-based Cim Mangement has invested 0.16% in Aspen Technology, Inc. (NASDAQ:AZPN). Employees Retirement System Of Ohio owns 35,257 shares or 0.01% of their US portfolio. Segall Bryant And Hamill Ltd Limited Liability Company stated it has 0.02% in Aspen Technology, Inc. (NASDAQ:AZPN). Paloma Prtnrs Mgmt Communications holds 0.02% or 19,768 shares in its portfolio. Teachers Retirement Sys Of The State Of Kentucky stated it has 0.01% in Aspen Technology, Inc. (NASDAQ:AZPN). Bbva Compass Bankshares Inc has invested 0.03% in Aspen Technology, Inc. (NASDAQ:AZPN). Acadian Asset Management Ltd Liability holds 39,427 shares or 0.01% of its portfolio. 171,009 were reported by Ameriprise. Axa holds 16,200 shares or 0% of its portfolio. Rhumbline Advisers reported 100,760 shares. 76,402 were reported by Qs Investors Limited Com. Verition Fund Management Ltd Liability Co has invested 0.03% in Aspen Technology, Inc. (NASDAQ:AZPN). Bessemer Gp reported 0.01% of its portfolio in Aspen Technology, Inc. (NASDAQ:AZPN). Alkeon Mgmt Limited Liability Company reported 0.27% in Aspen Technology, Inc. (NASDAQ:AZPN).

Among 9 analysts covering Aspen Technology (NASDAQ:AZPN), 3 have Buy rating, 2 Sell and 4 Hold. Therefore 33% are positive. Aspen Technology had 22 analyst reports since August 14, 2015 according to SRatingsIntel. On Friday, January 29 the stock rating was maintained by Canaccord Genuity with “Hold”. JP Morgan reinitiated Aspen Technology, Inc. (NASDAQ:AZPN) rating on Friday, April 29. JP Morgan has “Underweight” rating and $36 target. The stock has “Hold” rating by Robert W. Baird on Friday, October 6. The rating was initiated by Berenberg on Wednesday, August 23 with “Buy”. The company was upgraded on Friday, January 27 by Avondale. As per Tuesday, February 9, the company rating was initiated by Avondale. On Friday, June 9 the stock rating was maintained by Canaccord Genuity with “Hold”. The stock of Aspen Technology, Inc. (NASDAQ:AZPN) earned “Buy” rating by KeyBanc Capital Markets on Monday, September 18. On Saturday, August 15 the stock rating was downgraded by TheStreet to “Buy”. The stock has “Hold” rating by Benchmark on Wednesday, January 13.

Among 12 analysts covering Cytokinetics (NASDAQ:CYTK), 11 have Buy rating, 0 Sell and 1 Hold. Therefore 92% are positive. Cytokinetics had 21 analyst reports since July 24, 2015 according to SRatingsIntel. The firm earned “Buy” rating on Monday, November 9 by TH Capital. The rating was maintained by Cowen & Co on Thursday, August 3 with “Buy”. The rating was maintained by MLV on Friday, July 24 with “Buy”. Cantor Fitzgerald initiated Cytokinetics, Incorporated (NASDAQ:CYTK) on Friday, December 16 with “Overweight” rating. The stock of Cytokinetics, Incorporated (NASDAQ:CYTK) has “Buy” rating given on Tuesday, October 10 by Piper Jaffray. The firm has “Buy” rating given on Friday, October 27 by Needham. The stock of Cytokinetics, Incorporated (NASDAQ:CYTK) has “Buy” rating given on Tuesday, November 21 by Piper Jaffray. Morgan Stanley maintained Cytokinetics, Incorporated (NASDAQ:CYTK) rating on Wednesday, November 22. Morgan Stanley has “Buy” rating and $17.0 target. The stock of Cytokinetics, Incorporated (NASDAQ:CYTK) earned “Buy” rating by H.C. Wainwright on Friday, October 27. Needham maintained the shares of CYTK in report on Friday, September 15 with “Buy” rating.

Investors sentiment decreased to 1.39 in 2017 Q3. Its down 1.55, from 2.94 in 2017Q2. It is negative, as 16 investors sold CYTK shares while 30 reduced holdings. 21 funds opened positions while 43 raised stakes. 39.12 million shares or 3.53% more from 37.79 million shares in 2017Q2 were reported. Royal Bancorporation Of Canada holds 0% of its portfolio in Cytokinetics, Incorporated (NASDAQ:CYTK) for 17,181 shares. Tower Rech Llc (Trc) holds 1,701 shares or 0% of its portfolio. Parametric Portfolio Assocs Ltd Company accumulated 0% or 37,087 shares. Granite Prns Lc has 39,732 shares. Arizona State Retirement System has 0% invested in Cytokinetics, Incorporated (NASDAQ:CYTK) for 26,200 shares. Texas Permanent School Fund holds 36,829 shares or 0.01% of its portfolio. Essex Investment Limited Liability accumulated 78,758 shares. 25,599 are owned by Aqr Mgmt Lc. State Board Of Administration Of Florida Retirement Systems holds 0% or 25,519 shares in its portfolio. Northern Tru holds 471,858 shares or 0% of its portfolio. Rhumbline Advisers reported 88,056 shares. Tiaa Cref Management Ltd Liability Company has 0% invested in Cytokinetics, Incorporated (NASDAQ:CYTK) for 257,488 shares. Sphera Funds invested in 227,990 shares or 0.47% of the stock. Automobile Association owns 117,896 shares. Bvf Il reported 1.24M shares.

Since August 1, 2017, it had 0 insider purchases, and 12 selling transactions for $2.85 million activity. GAGE L PATRICK sold $72,944 worth of stock or 5,000 shares. $68,949 worth of Cytokinetics, Incorporated (NASDAQ:CYTK) shares were sold by Blum Robert I. Morgan Bradley Paul also sold $1.77M worth of Cytokinetics, Incorporated (NASDAQ:CYTK) shares. The insider McDowell Caryn Gordon sold $141,467.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>